Three drug manufacturers—including two that have imposed conditions on 340B contract pharmacy—posted public notices this week to 340B covered entities about refunds for charges above 340B ceiling prices.
Bristol Myers Squibb (BMS) and Novo Nordisk’s notices came to light yesterday and Ipsen’s on Wednesday. All appear on the U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) website.
Three drug manufacturers—including two that have imposed conditions on 340B contract pharmacy—posted public notices this week to 340B covered entities about refunds for charges above 340B ceiling prices.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
